Movement Alert｜CSPC PHARMA Intraday Rise 3.44% in Regular Trading, backed by new China trial starts for hypertension and tumor drugs

Market Focus11-04 13:32

On November 4, CSPC PHARMA saw an Intraday Rise of 3.44% in Regular Trading, with the stock trading at HK$8.125 and turnover reaching HK$561 million.

The clearest fresh catalyst was the companys disclosure on November 3 that it started two new clinical studies in China: a phase II trial of SYH2072 tablets for uncontrolled and resistant hypertension, and a phase I/II trial of SYS6088 injection for advanced solid tumors.

SYH2072 is described as a highly selective aldosterone synthase inhibitor targeting CYP11B2, with the phase II study designed as a multicenter, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety in patients whose blood pressure remains uncontrolled despite treatment with at least two antihypertensive drugs. Separately, SYS6088 entered a first-in-human phase I/II study focused on safety, tolerability, pharmacokinetics and preliminary antitumor activity in advanced solid tumors, with recruitment and screening now underway. The updates add to a recent string of pipeline catalysts for CSPC PHARMA across oncology, vaccines and metabolic disease.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1146929933?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-04 13:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146929933","market":"hk","top_or_hot":-1,"title":"Movement Alert｜CSPC PHARMA Intraday Rise 3.44% in Regular Trading, backed by new China trial starts for hypertension and tumor drugs","media":"Market Focus","content":"<p><p>On November 4, CSPC PHARMA saw an Intraday Rise of 3.44% in Regular Trading, with the stock trading at HK$8.125 and turnover reaching HK$561 million.</p><p>The clearest fresh catalyst was the companys disclosure on November 3 that it started two new clinical studies in China: a phase II trial of SYH2072 tablets for uncontrolled and resistant hypertension, and a phase I/II trial of SYS6088 injection for advanced solid tumors.</p><p>SYH2072 is described as a highly selective aldosterone synthase inhibitor targeting CYP11B2, with the phase II study designed as a multicenter, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety in patients whose blood pressure remains uncontrolled despite treatment with at least two antihypertensive drugs. Separately, SYS6088 entered a first-in-human phase I/II study focused on safety, tolerability, pharmacokinetics and preliminary antitumor activity in advanced solid tumors, with recruitment and screening now underway. The updates add to a recent string of pipeline catalysts for CSPC PHARMA across oncology, vaccines and metabolic disease.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CSPC PHARMA Intraday Rise 3.44% in Regular Trading, backed by new China trial starts for hypertension and tumor drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CSPC PHARMA Intraday Rise 3.44% in Regular Trading, backed by new China trial starts for hypertension and tumor drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-11-04 13:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On November 4, CSPC PHARMA saw an Intraday Rise of 3.44% in Regular Trading, with the stock trading at HK$8.125 and turnover reaching HK$561 million.</p><p>The clearest fresh catalyst was the companys disclosure on November 3 that it started two new clinical studies in China: a phase II trial of SYH2072 tablets for uncontrolled and resistant hypertension, and a phase I/II trial of SYS6088 injection for advanced solid tumors.</p><p>SYH2072 is described as a highly selective aldosterone synthase inhibitor targeting CYP11B2, with the phase II study designed as a multicenter, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety in patients whose blood pressure remains uncontrolled despite treatment with at least two antihypertensive drugs. Separately, SYS6088 entered a first-in-human phase I/II study focused on safety, tolerability, pharmacokinetics and preliminary antitumor activity in advanced solid tumors, with recruitment and screening now underway. The updates add to a recent string of pipeline catalysts for CSPC PHARMA across oncology, vaccines and metabolic disease.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1146929933","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146929933","pubTimestamp":1793770370,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On November 4, CSPC PHARMA saw an Intraday Rise of 3.44% in Regular Trading, with the stock trading at HK$8.125 and turnover reaching HK$561 million.The clearest fresh catalyst was the companys...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"走势提醒|石药集团常规交易盘中上涨3.44%，受中国高血压和肿瘤药物新试验启动的支撑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"On November 4, CSPC PHARMA saw an Intraday Rise of 3.44% in Regular Trading, with the stock trading at HK$8.125 and turnover reaching HK$561 million.The clearest fresh catalyst was the companys disclosure on November 3 that it started two new clinical studies in China: a phase II trial of SYH2072 tablets for uncontrolled and resistant hypertension, and a phase I/II trial of SYS6088 injection for advanced solid tumors.SYH2072 is described as a highly selective aldosterone synthase inhibitor targeting CYP11B2, with the phase II study designed as a multicenter, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety in patients whose blood pressure remains uncontrolled despite treatment with at least two antihypertensive drugs. Separately, SYS6088 entered a first-in-human phase I/II study focused on safety, tolerability, pharmacokinetics and preliminary antitumor activity in advanced solid tumors, with recruitment and screening now underway. The updates add to a recent string of pipeline catalysts for CSPC PHARMA across oncology, vaccines and metabolic disease.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146929933","isCrawlerRequest":true}